X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TORRENT PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA TORRENT PHARMA GLENMARK PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 12.2 27.2 44.8% View Chart
P/BV x 3.2 5.2 62.2% View Chart
Dividend Yield % 0.4 1.1 35.6%  

Financials

 GLENMARK PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
TORRENT PHARMA
Mar-17
GLENMARK PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9931,768 56.2%   
Low Rs7291,186 61.5%   
Sales per share (Unadj.) Rs325.5346.1 94.1%  
Earnings per share (Unadj.) Rs39.355.2 71.2%  
Cash flow per share (Unadj.) Rs48.773.3 66.4%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.20.9 24.5%  
Book value per share (Unadj.) Rs159.2257.1 61.9%  
Shares outstanding (eoy) m282.17169.22 166.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.3 62.0%   
Avg P/E ratio x21.926.8 81.9%  
P/CF ratio (eoy) x17.720.1 87.8%  
Price / Book Value ratio x5.45.7 94.2%  
Dividend payout %5.125.4 20.1%   
Avg Mkt Cap Rs m242,991249,887 97.2%   
No. of employees `00013.011.8 110.1%   
Total wages/salary Rs m16,4089,934 165.2%   
Avg. sales/employee Rs Th7,083.94,971.5 142.5%   
Avg. wages/employee Rs Th1,265.4843.2 150.1%   
Avg. net profit/employee Rs Th855.1792.4 107.9%   
INCOME DATA
Net Sales Rs m91,85758,569 156.8%  
Other income Rs m3742,233 16.7%   
Total revenues Rs m92,23060,802 151.7%   
Gross profit Rs m20,36713,773 147.9%  
Depreciation Rs m2,6443,069 86.1%   
Interest Rs m2,3732,056 115.5%   
Profit before tax Rs m15,72410,881 144.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8271,545 247.7%   
Profit after tax Rs m11,0889,336 118.8%  
Gross profit margin %22.223.5 94.3%  
Effective tax rate %24.314.2 171.4%   
Net profit margin %12.115.9 75.7%  
BALANCE SHEET DATA
Current assets Rs m68,74653,841 127.7%   
Current liabilities Rs m27,02731,612 85.5%   
Net working cap to sales %45.438.0 119.7%  
Current ratio x2.51.7 149.3%  
Inventory Days Days8597 87.5%  
Debtors Days Days9684 114.0%  
Net fixed assets Rs m24,13242,079 57.3%   
Share capital Rs m282846 33.3%   
"Free" reserves Rs m44,64342,655 104.7%   
Net worth Rs m44,92543,501 103.3%   
Long term debt Rs m45,36322,408 202.4%   
Total assets Rs m117,639101,250 116.2%  
Interest coverage x7.66.3 121.2%   
Debt to equity ratio x1.00.5 196.0%  
Sales to assets ratio x0.80.6 135.0%   
Return on assets %11.411.3 101.7%  
Return on equity %24.721.5 115.0%  
Return on capital %19.119.6 97.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15220,066 279.8%   
Fx outflow Rs m8,0845,304 152.4%   
Net fx Rs m48,06814,762 325.6%   
CASH FLOW
From Operations Rs m6,57410,127 64.9%  
From Investments Rs m-7,124-7,869 90.5%  
From Financial Activity Rs m5,432-1,918 -283.2%  
Net Cashflow Rs m1,992212 942.0%  

Share Holding

Indian Promoters % 48.3 71.5 67.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 7.0 98.3%  
FIIs % 34.4 12.6 273.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   56,727 26,511 214.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS